A Two-part, Randomised, Single-blind, Placebo-controlled, Single and Multiple Rising Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BI 3776528, Administered to Healthy Male Participants
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs BI 3776528 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 23 Jan 2025 Planned End Date changed from 31 Jan 2026 to 23 Dec 2025.
- 23 Jan 2025 Planned initiation date changed from 9 Jan 2025 to 23 Jan 2025.
- 27 Dec 2024 New trial record